业绩连续三年下滑 悦康药业(688658.SH)“救火式”赴港上市?

Core Viewpoint - The company, Yuyuan Pharmaceutical Group Co., Ltd., is facing significant financial challenges, including declining revenues and profits, prompting multiple fundraising efforts and a new H-share listing plan to diversify financing channels and enhance its international brand image [2][3][4][6]. Group 1: Company Overview - Yuyuan Pharmaceutical Group was established in 2001 and is headquartered in Beijing, focusing on new drug research and development, production, distribution, and international trade [2]. - The company has developed nine core R&D platforms, covering areas such as nucleic acid drugs, peptide drugs, traditional Chinese medicine, and high-end pharmaceuticals [2]. Group 2: Financial Performance - The company has experienced a continuous decline in performance over the past three years, with net profit attributable to the parent company decreasing by 38.53% in 2022, 44.87% in 2023, and 33.05% in 2024 [4]. - In the first three quarters of 2025, the company reported total revenue of 1.759 billion yuan, a year-on-year decrease of 41.20%, and a net loss of 148 million yuan, compared to a profit of 210 million yuan in the same period the previous year [6]. Group 3: Fundraising Efforts - The company announced plans to raise up to 300 million yuan through a private placement to support its main business projects and supplement working capital [3]. - Following its IPO, the company has initiated three fundraising actions in five years, indicating a tightening cash flow situation [3]. Group 4: Regulatory and Market Challenges - The company is under scrutiny due to allegations related to its core product, Ginkgo biloba extract injection, which faced accusations of "dual pricing" [3]. - In response to regulatory concerns, the company has committed to lowering the nationwide listed price of the product, which is expected to impact its financial performance [3]. Group 5: Shareholder Issues - The controlling shareholder, the Wei family, is facing difficulties with forced share sales, with 26.5 million shares auctioned for a total of 486 million yuan [7].